BNTC Company Profile and Key Details

BNTC has shown weak momentum, losing -4.2% over the past week and -25.69% over the past quarter, though year-to-date performance is down -13.66%. Short-term trend indicators are bullishly aligned (SMA20 -2.4%, SMA50 -6.5%, SMA200 -15.37%). The stock’s 14-day RSI is 46.02 (neutral), while the ATR of 0.73 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -34.75% below its high and over 13.6% above its low. Average 10-day trading volume of 101.42 thousand shares is below the 3-month average of 155.60 thousand, indicating normal recent market interest.

Benitec Biopharma Inc. generated EPS of -$0.93 over the past year. Five-year average earnings growth is 62.31%. Wall Street analysts project EPS growth of 5.01% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $20.00. The high target offers 187.36% upside. The low target suggests 64.2% downside. The mean target is $28.83. This offers 136.7% upside. Benitec Biopharma Inc. earnings surprise history is a mixed track record. The quarter that ended February 12, 2026, missed forecasts by 13.04%. The prior quarter beat by -37.14%. Over the last six quarters, Apple has recorded several small beats. These include -64.0% in February 14, 2025.

Benitec Biopharma Inc. has 26.25 million shares outstanding. The public float is 12.57 million shares, elevated short interest at 9.72% of float. This equals 1.39 million shares. The short ratio is 22.33 days. Institutional investors hold 93.61% of the float. Insiders own 3.12%. SUVRETTA CAPITAL MANAGEMENT, LLC holds 1.85 million shares, Oliveira Steven Michael has 1.00 million shares and BUCHI J KEVIN has 51.81 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Benitec Biopharma Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.68. This means the shares are trading above this model’s fair value.

Benitec Biopharma Inc. (NASDAQ:BNTC) closed at $12.18 USD, gaining $0.23 (1.92%) from the previous close of $11.95. The stock is currently mid-range between its 52-week high and low $9.85 and $17.15. With a market capitalization of about $319.69 million, Benitec Biopharma Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.28). Key stats such as the average daily volume over the past year has been around 158.67 thousand shares, volume is running light vs its 52-week average. Headquartered in Hayward, CA, Benitec Biopharma Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jerel A. Banks, the company employs approximately 16 people and listed since June 24, 2014. Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines.

Benitec Biopharma Inc. trades at a P/E ratio of -12.14, slightly below the S&P 500 average, with a price-to-sales ratio of 577.1 and a price-to-book ratio of 3.0 trading at moderately above to book value. The P/FCF stands at -17.1, also above market averages.

Our AI price prediction model suggests that Benitec Biopharma Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.83%, with price expected at $12.89 by May 18, 2026, within a range of $11.89 to $13.90 3-Month Outlook: Projected fall of -19.7%, reaching $9.78 by July 31, 2026, with a range of $9.46 to $10.11. 1-Year Outlook: Projected gain of 128.98%, with price at $27.89 by May 04, 2027, within a range of $27.62 to $28.11.

Benitec Biopharma Inc. (NASDAQ:BNTC) shares are down -13.66% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Benitec Biopharma Inc. trading at a premium to the broader market with a P/E of -12.14. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.48, suggesting 59.93% upside. Our AI forecast model points to short-term strength (5.83% over two weeks), a medium-term fall (-19.7% over three months), and a longer-term gain (128.98% over one year), with expected trading ranges indicating moderate volatility.